Welcome to the web pages of Øyvind S. Bruland
On this web site you will find information about my scientific work within cancer research,
as well as other activities.
My clinical experience and research are mainly devoted to primary bone and soft tissue cancers (sarcomas) and skeletal metastases from prostate cancer and breast cancer. In particular, targeted radionuclide therapy, e.g. Alpharadin (Algeta), based on Radium-223, is currently at center stage.
|Seksjonsoverlege Øyvind Bruland
Det Norske Radiumhospital
|Professor of Clinical Oncology
Department of Medical Oncology & Radiotherapy
The Norwegian Radium Hospital
N-0310 Oslo, NORWAY
Recent updates and publications
Handbook of Cancer-Related Bone Disease
This handbook of 2010 compiles a clear summary of clinically relevant information with recommendations for treatment of cancer-related bone disease. By activating the hyperlink below, you may find information on the book with its contents and preface, contributors and a pdf of a chapter on "Radio-isotope treatments for bone metastases".
Handbook of Cancer-Related Bone Disease (PDF) (2nd edtition)
The book is available to order from the distributor's website: click here
A comprehensive text on osteosarcoma
In essence the scope and intensive coverage of the book provides a historical perspective of the advances made over the past 30 years and emerging concepts and prospects for new diagnostic and therapeutic approaches. This is based upon past experiences and new discoveries. It also provides a unique opportunity for pediatric and adult medical oncologists, physicians in training, orthopedic surgeons, pathologists, radiologists, radiotherapists, oncology nurses and allied professionals involved in the care of pediatric/adolescent patients with osteosarcoma to become acquainted with prevailing methods of treatment and new and evolving concepts and developments.
Click here to view a flyer on the book (Word format)
Click here to view table of contents
A link to this book from Springer Verlag: click here
Download the book file directly here (50 MB)
An interview with professor Øyvind S. Bruland has recently been published on the University of Oslo web page, in their popular scientific series "Interviews with researchers" (in Norwegian). It is entitled "Raketter og tverrfaglighet i kampen mot kreft" ("Rockets and interdisciplinarity in the fight against cancer").
Øyvind S. Bruland's research is mainly devoted to primary bone and soft tissue cancers (sarcomas) and skeletal metastases from prostate cancer and breast cancer.
Life with Cancer
We compiled this book to shed light on several aspects of cancer - a disease that engenders more fear and uncertainty than most other prevalent diseases. In the popular science tradition, this book discusses causes and treatments of cancer, late effects that may develop after a cure is effected, some new inroads being made in cancer research, and we meet cancer patients and relatives in moving encounters that offer precious insight.Click here
for more information on this illustrated book, with its content, foreword, author biographies and a PDF of my own chapter: "Cancer - Causes and Treatment."
Publication in Lancet Oncology
Nilsson S, Franzen L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennernas B, Petersson U, Johannessen DC, Sokal M, Pigott K, Yachnin J, Garkavij M, Strang P, Harmenberg J, Bolstad B, Bruland OS. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.
Lancet Oncol. 2007 Jul;8(7):587-94.Download article in PDF format
Publication in Blood, 2007
Our group have recently published a translational study on alpha-particle based radiomimmunotherapy in the high-impact journal Blood
You may view a pdf of the paper here
Alpharadin (Radium-223) - Further positive results
A comprehensive review on the use of bone-seeking radiopharmaceuticals; including Alpharadin, in bone-metastatic patients was publisehed in Cancer Treatment Reviews, 2012. Click here for a pdf of the publication
Some key issues to understand this promising new treatment strategy
- Tumor biology
- Radio biology
- Target distribution
- Phase 3 + Video
Click here to view the presentation (PDF format)
In this review - printed in the September 2008 issue of "Current Radiopharmaceuticals" - we present the evolution from radiochemical discovery to clinical applications of radium-223 (Alpharadin).Click here
to view the table of contents (PDF rormat)Click here
do download a pdf of the manuscript
Results from a Phase II randomized clinical trial of the novel alpha-emitting bone-seeker Alpharadin™ in patients with late-stage hormone-refractory prostate cancer (HRPC), including significant survival data, were presented at the American Society of Clinical Oncology (ASCO) Prostate Cancer Symposium (Orlando, Florida, USA February 22-24, 2007).
You may view the poster here (Hyperlink to pdf
Treatment of bone metastasis